AlveoliX AG: Funding, Investors & Team (Sep 2026)
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs. AlveoliX aims at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs’ responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing.
AlveoliX AG has raised $1.2M across 1 funding round on record, the most recent an undisclosed round of $1.2M announced in Jun 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
AlveoliX AG Company Profile and Key Stats
Latest funding round on record: Jun 2026.
AlveoliX AG Funding Rounds
AlveoliX AG Founders and Leadership Team
No contact details are on record for this team yet.
AlveoliX AG Funding Compared to Other Biotechnology Startups
AlveoliX AG's latest round of $1.2M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like AlveoliX AG in Biotechnology and Berne
Companies Similar to AlveoliX AG
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Pharvaris is a clinical-stage company working on bringing a new oral bradykinin B2 receptor antagonist to…
AlveoliX AG Funding FAQs
What does AlveoliX AG do?
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs. AlveoliX aims at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs’ responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing.
How much funding has AlveoliX AG raised?
AlveoliX AG has raised $1.2M across 1 round on record. The most recent is an undisclosed round of $1.2M announced in Jun 2026.
When did AlveoliX AG last raise funding?
AlveoliX AG's most recent funding round on record is an undisclosed round of $1.2M, announced in Jun 2026.
Who founded AlveoliX AG?
FundedIQ lists Janick Stucki (Founder) at AlveoliX AG.
Where is AlveoliX AG headquartered?
AlveoliX AG is based in Berne, Bern, Switzerland.
How many employees does AlveoliX AG have?
AlveoliX AG is in the 11-50 employee band.
How does AlveoliX AG's funding compare to other Biotechnology startups?
AlveoliX AG's latest round of $1.2M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's AlveoliX AG Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for AlveoliX AG is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.